ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023
02 August 2023 - 1:00PM
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an
end-to-end commercial biopharmaceutical company dedicated to
manufacturing, marketing, and developing specialty plasma-derived
biologics, today announced that it will report second quarter
financial results on August 9, 2023, after the U.S. financial
markets close. ADMA’s management team will host a live conference
call and audio webcast on that date at 4:30 p.m. ET to discuss its
financial results and other Company updates.
To access the conference call, participants may
register for the call here to receive the dial-in
numbers and unique PIN to access the call seamlessly. It is
recommended that you join 10 minutes prior to the event start
(although you may register and dial in at any time during the
call). A live audio webcast of the call will be available under
“Events & Webcasts” in the investor section of the Company’s
website,
https://ir.admabiologics.com/events-webcasts. An
archived webcast will be available on the Company’s website
approximately two hours after the event.
About ADMA Biologics, Inc.
(ADMA)
ADMA Biologics is an end-to-end commercial
biopharmaceutical company dedicated to manufacturing, marketing and
developing specialty plasma-derived biologics for the treatment of
immunodeficient patients at risk for infection and others at risk
for certain infectious diseases. ADMA currently manufactures and
markets three United States Food and Drug Administration
(FDA)-approved plasma-derived biologics for the treatment of immune
deficiencies and the prevention of certain infectious diseases:
BIVIGAM® (immune globulin intravenous, human) for the treatment of
primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin
intravenous, human – slra 10% liquid) for the treatment of PI; and
NABI-HB® (hepatitis B immune globulin, human) to provide enhanced
immunity against the hepatitis B virus. ADMA manufactures its
immune globulin products at its FDA-licensed plasma fractionation
and purification facility located in Boca Raton, Florida. Through
its ADMA BioCenters subsidiary, ADMA also operates as an
FDA-approved source plasma collector in the U.S., which provides a
portion of its blood plasma for the manufacture of its products.
ADMA’s mission is to manufacture, market and develop specialty
plasma-derived, human immune globulins targeted to niche patient
populations for the treatment and prevention of certain infectious
diseases and management of immune compromised patient populations
who suffer from an underlying immune deficiency, or who may be
immune compromised for other medical reasons. ADMA has received
U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and
10,259,865 and European Patent No. 3375789, among others, related
to certain aspects of its products and product candidates. For more
information, please visit
www.admabiologics.com.
COMPANY CONTACT: Skyler
BloomSenior Director, Business Development & Corporate Strategy
| 201-478-5552 | sbloom@admabio.com
INVESTOR RELATIONS
CONTACT:Jason FinkelsteinManaging Director, Argot Partners
| 212-600-1902 | jason@argotpartners.com
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
Von Apr 2023 bis Apr 2024